FDA warned Clinical Resolution Laboratory in Brea, CA, about CGMP failures and unapproved OTC drugs.
What happened
FDA inspected the Brea, California drug manufacturing facility from April 6 to April 27, 2021. It found no documented process validation, inadequate cleaning validation for shared equipment, release of an OTC topical batch before final lab testing, and an inadequate quality unit. FDA also found several OTC products marketed as skin bleaching, anorectal, external analgesic or antifungal drugs without approved applications.
What FDA found
The company lacked documented validation of its manufacturing processes for its OTC drug products.
21 CFR 211.100(a)It did not validate cleaning of shared manufacturing equipment, including microbiological testing.
21 CFR 211.67(b)It released an OTC topical drug lot before final contract lab testing for active ingredient strength and microbiological quality was reported.
21 CFR 211.165(a)Its quality unit lacked procedures, training, investigations, complaint handling and contract lab quality agreements.
21 CFR 211.22Several products were unapproved new drugs because they were marketed for uses not covered by OTC monographs or lacked approved applications.
FD&C Act section 505(a), 21 U.S.C. 355(a)The products were also misbranded under section 502(ee).
FD&C Act section 502(ee), 21 U.S.C. 352(ee)
What FDA wants
FDA tells the company to provide detailed corrective action plans, validation and cleaning protocols, batch reviews, and an independent assessment of its quality unit, and recommends engaging a CGMP consultant. It asks for these responses in writing; the provided letter excerpt does not state a response deadline.
Who should pay attention
- brands that buy OTC topical products from this contract manufacturer
- companies using shared equipment for drugs and cosmetics
- quality teams managing contract labs and supplier quality agreements
This is a summary. Read the original letter on fda.gov.